Abbott Reports Xience Stent Launch Off To A Good Start
This article was originally published in The Gray Sheet
Executive Summary
Abbott says sales of its Xience V everolimus-eluting coronary stent during its first two weeks on the U.S. market have exceeded the company's pre-launch projections
You may also be interested in...
Boston Scientific Plans 2008 Post-Warning Letter Interventional Launches
Boston Scientific plans to launch four new interventional cardiology products in 2008 after resolving a two-and-a-half-year-old company-wide FDA warning letter
Boston Scientific Plans 2008 Post-Warning Letter Interventional Launches
Boston Scientific plans to launch four new interventional cardiology products in 2008 after resolving a two-and-a-half-year-old company-wide FDA warning letter
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Abbott remains confident that it will gain 25% to 30% share of the U.S. drug-eluting stent market over the next year now that it has launched its Xience V everolimus-eluting stent